Trial record 31 of 115 for: "Viral Infectious Disease" | "Ledipasvir"
Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed-Dose Combination (FDC) for 6 Weeks in Adults With Acute Genotype 1 or 4 Hepatitis C Virus (HCV) and Chronic Human Immunodeficiency Virus (HIV)-1 Co-Infection
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02457611|
Recruitment Status : Completed
First Posted : May 29, 2015
Results First Posted : February 28, 2017
Last Update Posted : November 16, 2018
Information provided by (Responsible Party):
|Study Design||Intervention Model: Single Group Assignment; Masking: None (Open Label); Primary Purpose: Treatment|
Hepatitis C Infection With HIV Co-Infection
|Recruitment Details||Participants were enrolled at study sites in Germany and the United Kingdom. The first participant was screened on 11 June 2015. The last study visit occurred on 8 January 2016.|
|Pre-assignment Details||34 participants were screened.|
There were no limitations affecting the analysis or results.